All In Biotech

Drug Trial Radar · NCT04841369

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

A Randomized,Blind, Positive-controlled Phase III Clinical Trial to Evaluate the Safety and Immunogencity of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT) in Healthy People Aged 6 Weeks and Above

Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,420 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,420

Actual

Start

Apr 13, 2021

Primary completion

Mar 30, 2022

Study completion Sep 20, 2022

Sponsor

Lead sponsor
CanSino Biologics Inc.Industry
Sponsor type
Industry
Collaborators
Henan Center for Disease Control and Prevention
First posted
Apr 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 weeks
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.Since the licensure of PCV7 and PCV13,the reported overall decline in invasive pneumococcal disease in hospitalized children younger than 5 years several years is approximately 60% in Western countries.This is a single center,blind, randomized, positive-controlled clinical trial.The purpose of this study is to preliminary evaluate the safety of PCV13i vaccine in subjects at age of 7 months and above,and to investigate the safety and immunogenicity of PCV13i vaccine at age of 2 and 3 months,compared to PCV13.

Conditions

  • Pneumococcal Infections
  • Streptococcal Infections
  • Bacterial Infections

Interventions

  • 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)Biological

    0.5mL,Intramuscular

  • 13-Valent Pneumococcal Polysaccharide Conjugate VaccineBiological

    0.5mL,Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of PCV13i in preventing pneumococcal infectionsTime frame: Within 7 days post each vaccination
  2. Safety of PCV13i in preventing pneumococcal infectionsTime frame: Within 30 days post each vaccination
  3. Immunogenicity of PCV13i in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)Time frame: 30 days post three doses
  4. Immunogenicity of PCV13i in subjects of 7 to 11 months old (Arm 4A-4B)Time frame: 30 days post three doses
  5. Immunogenicity of PCV13i in subjects of 12 months to 5 years old (Arm 5A, 5B, 6A, 6B)Time frame: 30 days post last dose of vaccination
  6. Immunogenicity of PCV13i in subjects of age 50 years old and above (Arm 6A, 6B, 7A, 7B)Time frame: 30 days post vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Neihuang Center for Disease Control and Prevention

    Anyang, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.